The structure and function of the glucagon-like peptide-1 receptor and its ligands

被引:211
|
作者
Donnelly, Dan [1 ]
机构
[1] Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England
关键词
GLP-1; GPCR; exendin-4; exenatide; liraglutide; diabetes; glucagon; insulin; VASOACTIVE-INTESTINAL-PEPTIDE; GUINEA-PIG PANCREAS; N-TERMINAL DOMAIN; GLP-1; 7-36; AMIDE; IN-VITRO; INSULIN-SECRETION; DISPERSED ACINI; EXTRACELLULAR DOMAIN; PARATHYROID-HORMONE; BIOLOGICAL-ACTIVITY;
D O I
10.1111/j.1476-5381.2011.01687.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple effects have generated a great deal of interest in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R) in order to treat type 2 diabetes. This review article summarizes the literature regarding the discovery of GLP-1 and its physiological functions. The structure, function and sequenceactivity relationships of the hormone and its natural analogue exendin-4 (Ex4) are reviewed in detail. The current knowledge of the structure of GLP-1R, a Family B GPCR, is summarized and discussed, before its known interactions with the principle peptide ligands are described and summarized. Finally, progress in discovering non-peptide ligands of GLP-1R is reviewed. GLP-1 is clearly an important hormone linking nutrient consumption with blood sugar control, and therefore knowledge of its structure, function and mechanism of action is of great importance.
引用
收藏
页码:27 / 41
页数:15
相关论文
共 50 条
  • [41] Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
    De Ycaza, Ana E. Espinosa
    Brito, Juan P.
    McCoy, Rozalina G.
    Shao, Hui
    Ospina, Naykky Singh
    THYROID, 2024, 34 (04) : 403 - 418
  • [42] Rational Design of a Humanized Glucagon-Like Peptide-1 Receptor Agonist Antibody
    Zhang, Yong
    Zou, Huafei
    Wang, Ying
    Caballero, Dawna
    Gonzalez, Jose
    Chao, Elizabeth
    Welzel, Gus
    Shen, Weijun
    Wang, Danling
    Schultz, Peter G.
    Wang, Feng
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (07) : 2126 - 2130
  • [43] Regulation of glucose kinetics during exercise by the glucagon-like peptide-1 receptor
    Burmeister, M. A.
    Bracy, D. P.
    James, F. D.
    Holt, R. M.
    Ayala, J.
    King, E. M.
    Wasserman, D. H.
    Drucker, D. J.
    Ayala, J. E.
    JOURNAL OF PHYSIOLOGY-LONDON, 2012, 590 (20): : 5245 - 5255
  • [44] Potential kidney protective effects of glucagon-like peptide-1 receptor agonists
    Trevella, Philippa
    Ekinci, Elif I.
    Macisaac, Richard J.
    NEPHROLOGY, 2024, 29 (08) : 457 - 469
  • [45] Conformation Research of Shorted Glucagon-like Peptide-1
    Nie Xin-Hua
    Zhang Tao
    Li Yuan
    Zheng Xue-Fang
    Gao Hong-Yu
    Tang Qian
    CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE, 2010, 31 (07): : 1337 - 1341
  • [46] Mechanisms for the cardiovascular effects of glucagon-like peptide-1
    Poudyal, H.
    ACTA PHYSIOLOGICA, 2016, 216 (03) : 277 - 313
  • [47] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Sarraju, Ashish
    Kim, Sun H.
    Knowles, Joshua W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (02) : 1 - 8
  • [48] The effects of glucagon-like peptide-1 on the beta cell
    Vilsboll, T.
    DIABETES OBESITY & METABOLISM, 2009, 11 : 11 - 18
  • [49] Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life
    Shchendrygina, Anastasia
    Rakisheva, Amina
    Giverts, Ilya
    Rustamova, Yasmin
    Soloveva, Anzhela
    CARDIAC FAILURE REVIEW, 2024, 10
  • [50] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1380 - 1384